Clinical significance of bone metastasis with extraosseous soft-tissue mass in prostate cancer patients

Clinical significance of bone metastasis with extraosseous soft-tissue mass in prostate cancer patients - Clinical significance of bone metastasis with extraosseous soft-tissue mass in prostate cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030633

Enrollment

720

Registered

2018-02-01

Start date

2017-10-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with histopathologically or clinically diagnosed PC

Exclusion criteria

Exclusion criteria: Patients without bone metastasis

Design outcomes

Primary

Measure	Time frame
age, T/N stage, organ metastases, Gleason sum score, initial clinical symptoms, treatment methods, sites of PCBMs, initial PSA level (ng/mL), PSA nadir (ng/mL), PSA reduction rate (%), time from the initiation of therapy to PSA nadir (day), PSA doubling time (day), PSA progression-free survival (day), and overall survival (day)	—

Countries

Japan

Contacts

Public ContactHiroki Kato

Gifu University School of Medicine Radiology

hkato@gifu-u.ac.jp058-230-6439

Outcome results